Structure via PubChem · Public domain (PubChem)
blonanserin
Sign in to saveAlso known as AD 5423, AD-5423
Blonanserin, sold under the brand name Lonasen, is a relatively new atypical antipsychotic (approved by PMDA in January 2008) commercialized by Dainippon Sumitomo Pharma in Japan and Korea for the treatment of schizophrenia. Relative to many other antipsychotics, blonanserin has an improved tolerability profile, lacking side effects such as extrapyramidal symptoms, excessive sedation, or hypotension. As with many second-generation (atypical) antipsychotics it is significantly more efficacious in the treatment of the negative symptoms of schizophrenia compared to first-generation (typical) anti
In the Vinony graph
Vinony's link graph records 1,643 inbound references to blonanserin, and connects out to fluphenazine, zuclopenthixol and pipotiazine.
It is catalogued under topics including 4-Fluorophenyl compounds, 5-HT2 antagonists and Atypical antipsychotics.
Vinony links it to 11 Wikipedia language editions.
Key facts
- Drug.IUPAC_name
- 2-(4-ethylpiperazin-1-yl)-4-(4-fluorophenyl)-5,6,7,8,9,10-hexahydrocycloocta[b]pyridine
- Drug.image
- Blonanserin.svg
- Drug.image_class
- skin-invert-image
- Drug.width
- 260
- Drug.image2
- Blonanserin-xtal-2012-ball-and-stick.png
- Drug.image_class2
- bg-transparent
- Drug.width2
- 260
- Drug.tradename
- Lonasen
- Drug.legal_status
- Rx-only
- Drug.routes_of_administration
- By mouth
- Drug.bioavailability
- 55%
- Drug.metabolism
- CYP3A4
- Drug.elimination_half life
- 12 h
- Drug.excretion
- 59% (urine), 30% (faeces)
- Drug.CAS_number
- 132810-10-7
- Drug.ATC_prefix
- none
- Drug.PubChem
- 125564
- Drug.ChEMBL
- 178803
via Wikipedia infobox
Chemical data
- Formula
- C23H30FN3
- Molecular weight
- 367.5 g/mol
- IUPAC name
- 2-(4-ethylpiperazin-1-yl)-4-(4-fluorophenyl)-5,6,7,8,9,10-hexahydrocycloocta[b]pyridine
- SMILES
- CCN1CCN(CC1)C2=NC3=C(CCCCCC3)C(=C2)C4=CC=C(C=C4)F
- InChIKey
- XVGOZDAJGBALKS-UHFFFAOYSA-N
- XLogP
- 5.5
- Polar surface area
- 19.4 Ų
- H-bond donors
- 0
- H-bond acceptors
- 4
- Formal charge
- 0
via PubChem
Drug data · ChEMBL
- Max clinical phase
- Approved
- Molecule type
- Small molecule
- Admin. routes
- oral
- Indications
- schizophrenia
via ChEMBL · EBI
Wikidata facts
- Subclass of
- chemical compound
- Mass
- 367.242376
- Has use
- medication
Show 4 more facts
- chemical formula
- C₂₃H₃₀FN₃
- World Health Organisation international non-proprietary name
- blonanserin
- canonical SMILES
- CCN1CCN(CC1)C2=NC3=C(CCCCCC3)C(=C2)C4=CC=C(C=C4)F
- Commons category
- Blonanserin
Sources (2)
via Wikidata · CC0
~6 min read
Encyclopedic overview
9 sectionsContents
- Medical uses
- Adverse effects
- Pharmacology
- Pharmacodynamics
- Action at the Dopamine-D<sub>3</sub> receptor
- Pharmacokinetics
- Effects of food intake
- See also
- References
Blonanserin, sold under the brand name Lonasen, is a relatively new atypical antipsychotic (approved by PMDA in January 2008) commercialized by Dainippon Sumitomo Pharma in Japan and Korea for the treatment of schizophrenia. Relative to many other antipsychotics, blonanserin has an improved tolerability profile, lacking side effects such as extrapyramidal symptoms, excessive sedation, or hypotension. As with many second-generation (atypical) antipsychotics it is significantly more efficacious in the treatment of the negative symptoms of schizophrenia compared to first-generation (typical) antipsychotics such as haloperidol.
==Medical uses== Blonanserin is used to treat schizophrenia in Japan and South Korea but not in the US.
Excerpted from Wikipedia’s “blonanserin” article, available under the CC BY-SA 4.0 licence.